November 16, 2026

Coronary Calcium Score Management: Treatment, LDL Goals & Heart Disease Prevention

A high coronary calcium score does not automatically mean you need a stent or stress test. Learn how Revolution Health approaches cholesterol reduction, metabolic health, and comprehensive cardiovascular prevention.

Coronary Calcium Score Management: Treatment, LDL Goals & Heart Disease Prevention

Your Coronary Calcium Score Is a Warning — and an Opportunity

A coronary artery calcium (CAC) score measures the amount of calcified plaque in the arteries supplying blood to your heart. It helps us identify coronary atherosclerosis, often years before symptoms develop.

A higher score means more calcified plaque and generally greater cardiovascular risk. However, an elevated calcium score does not mean a heart attack is inevitable.

It means we have identified a problem that deserves attention.

At Revolution Health & Wellness Clinic, our objective is not simply to lower cholesterol. We want to identify and address the underlying factors contributing to cardiovascular disease, stabilize existing plaque, improve metabolic health, and reduce your lifetime risk of heart attack and stroke.

If you have not already reviewed the basics of this test, start with our article: Understanding Your Coronary Artery Calcium Score.

What Does Your Calcium Score Mean?

CAC Score Interpretation Typical Management
0 No detectable calcified plaque Lifestyle optimization and individualized risk assessment
1–99 Mild calcified plaque burden Risk-factor management; cholesterol treatment based on age, percentile, and overall risk
100–299 Moderate plaque burden Lipid-lowering treatment generally recommended
300–999 Severe plaque burden Aggressive cholesterol reduction and comprehensive prevention
1,000+ Extensive plaque burden Intensive preventive treatment and careful clinical follow-up

A CAC score of 300 or higher is particularly important. Research suggests that some individuals with scores in this range have cardiovascular event rates approaching those of patients with established cardiovascular disease.

Consequently, we often treat these patients aggressively even when they feel perfectly healthy.

Remember: A calcium score measures calcified plaque burden. It does not directly tell us how severely an artery is narrowed.

Why We Treat Coronary Calcium Even When You Have No Symptoms

Coronary atherosclerosis can develop silently for decades.

Many heart attacks occur when an unstable plaque ruptures and triggers a blood clot. This can happen even when an artery was not previously severely narrowed.

Our treatment therefore focuses on reducing the likelihood of plaque progression, inflammation, rupture, and clot formation.

For patients without symptoms, aggressive prevention is often more appropriate than immediately ordering stress tests or invasive cardiac procedures.

For example, a patient with a CAC score of 842 and a coronary CT angiogram showing only 30–40% narrowing may benefit most from intensive preventive treatment rather than a stent or cardiac catheterization.

That approach changes if concerning symptoms develop or other findings suggest significant obstruction.

1. Lower LDL Cholesterol Aggressively

One of our most important goals is reducing exposure to atherogenic cholesterol particles.

LDL cholesterol contributes to plaque formation within the arterial wall. Lowering LDL reduces future cardiovascular events, particularly in patients with substantial coronary atherosclerosis.

Our LDL Treatment Goals

For patients with a CAC score of 300 or higher, we commonly pursue:

  • LDL-C below 70 mg/dL, with an intensive goal of below 55 mg/dL when appropriate.

  • At least a 50% reduction from pretreatment LDL cholesterol.

  • Non-HDL cholesterol below 100 mg/dL, preferably below 85 mg/dL for patients receiving intensive treatment.

These targets are individualized according to overall cardiovascular risk, medication tolerance, and other medical conditions.

Medications We Commonly Consider

Statins: Rosuvastatin and atorvastatin are frequently our first choices. They lower LDL cholesterol substantially and reduce cardiovascular events.

Ezetimibe: This medication reduces intestinal cholesterol absorption and can provide additional LDL reduction when combined with a statin.

PCSK9 inhibitors: These injectable medications can produce substantial additional LDL reductions when needed.

Bempedoic acid: An alternative or additional option for selected patients, particularly those who have difficulty tolerating statins.

We typically recheck cholesterol approximately 4–12 weeks after initiating or changing treatment.

An important point: Statins can increase the density of calcium within existing plaque as plaques stabilize. Therefore, an increasing calcium score during treatment does not necessarily indicate worsening disease.

Our goal is fewer cardiovascular events, not simply a lower number on a CT scan.

2. Should You Take Aspirin?

Aspirin reduces platelet aggregation and can help prevent blood clot formation.

However, aspirin also increases bleeding risk.

For patients with substantial coronary calcium, particularly CAC scores above 100–300, aspirin may provide benefit when bleeding risk is low.

Age is an important consideration. Current primary-prevention recommendations generally discourage starting aspirin routinely after age 60 because bleeding risk increases with age.

At Revolution Health, we evaluate aspirin individually, considering:

  • Coronary plaque burden

  • Age and overall cardiovascular risk

  • Previous gastrointestinal bleeding or ulcers

  • Use of anticoagulants or anti-inflammatory medications

  • Kidney and liver function

  • Other bleeding risk factors

Aspirin 81 mg daily may be appropriate for selected patients, but it is not automatically recommended for everyone with an elevated CAC score.

3. Optimize the Other Cardiovascular Risk Factors

Cholesterol is only one component of cardiovascular disease.

Atherosclerosis develops through interactions involving inflammation, insulin resistance, blood pressure, vascular dysfunction, body composition, genetics, and other metabolic factors.

This is why our cardiovascular evaluations extend well beyond a standard cholesterol panel.

We have previously discussed these issues in detail in The Top 25 Risk Factors for Cardiovascular Disease.

What We Monitor

Depending on your individual risk profile, our evaluation may include:

  • Standard lipid panel, ApoB, and lipoprotein(a)

  • Blood pressure and vascular health

  • Fasting glucose, insulin, and hemoglobin A1c

  • Inflammatory markers such as hs-CRP

  • Kidney and liver function

  • Thyroid function when indicated

  • Body composition and visceral fat

  • Smoking, sleep, physical activity, and nutritional habits

ApoB is particularly useful because it helps estimate the number of atherogenic lipoprotein particles circulating in your bloodstream.

Lipoprotein(a), or Lp(a), is another important risk factor that is largely genetically determined. We generally recommend measuring it at least once during adulthood.

Visceral Fat Matters

One of the most overlooked cardiovascular risk factors is visceral fat — the fat surrounding internal organs.

Visceral fat is metabolically active and contributes to insulin resistance, inflammation, abnormal cholesterol metabolism, and elevated cardiovascular risk.

At Revolution Health, we use body-composition measurements to monitor visceral fat and guide treatment.

Our preferred optimization target is less than 2 pounds of measured visceral fat, recognizing that this is a clinic-specific goal rather than a universally established medical cutoff.

For a patient with more than 3 pounds of visceral fat, reducing that burden is an important part of our comprehensive treatment strategy.

The objective is not simply weight loss. It is improving metabolic health while preserving muscle mass.

4. Nutrition, Exercise, and Lifestyle

Medication can substantially reduce cardiovascular risk, but lifestyle interventions remain essential.

We encourage a nutrient-dense, Mediterranean-style dietary pattern emphasizing vegetables, fruits, nuts, olive oil, appropriate protein sources, and minimally processed foods.

Regular exercise improves insulin sensitivity, blood pressure, endothelial function, and cardiovascular fitness.

Our typical recommendations include:

  • At least 150 minutes of moderate aerobic activity weekly, as tolerated

  • Resistance training to preserve muscle mass and metabolic function

  • Reduction of excess visceral fat

  • Consistent, restorative sleep

  • Smoking cessation

  • Blood pressure management, commonly targeting below 130/80 mm Hg when appropriate

We also address sleep apnea, metabolic dysfunction, and other conditions that may contribute to cardiovascular risk.

For additional strategies, read How to Improve Cardiovascular Disease Risk.

5. Intravenous Vitamin C: An Additional Cardiovascular Strategy

Beyond conventional treatment, we also consider therapies that may improve vascular function and address the biological processes contributing to atherosclerosis.

Intravenous vitamin C is one option worth discussing as part of a comprehensive cardiovascular optimization program.

Vitamin C participates in several processes relevant to cardiovascular health:

  • Collagen synthesis: Supports the structural integrity of blood vessels.

  • Antioxidant activity: Helps protect cellular structures and lipids from oxidative damage.

  • Endothelial function: May support nitric oxide availability and normal vascular function.

  • Inflammatory regulation: Influences biological pathways involved in vascular inflammation.

  • Metabolic health: Participates in cellular antioxidant systems and other metabolic processes.

These mechanisms provide a rationale for considering vitamin C in selected patients with cardiovascular risk factors.

Dr. Mitchell Ghen and other integrative practitioners have discussed high-dose intravenous vitamin C as a potential strategy for addressing oxidative stress and vascular health, including hypotheses involving coronary calcification.

We consider this an interesting therapeutic approach, particularly because oxidative stress and endothelial dysfunction contribute to atherosclerosis.

Should You Consider IV Vitamin C?

For appropriate patients, we believe IV vitamin C deserves consideration as an adjunctive cardiovascular wellness intervention, alongside proven preventive treatments.

However, it is important to distinguish biological potential from demonstrated clinical outcomes. Current evidence does not establish that IV vitamin C reverses coronary calcium, reduces heart attacks, or improves survival.

Patients considering high-dose infusions should undergo appropriate screening, including kidney function and G6PD status, because significant adverse effects can occur in susceptible individuals.

IV vitamin C should complement, rather than replace, cholesterol reduction, blood pressure control, exercise, and other established preventive measures.

6. Cardiovascular Peptides: Emerging Opportunities

Peptide research is expanding our understanding of mitochondrial function, cellular repair, inflammation, and cardiovascular recovery.

Although these therapies are not established treatments for coronary atherosclerosis, several peptides have mechanisms that make them interesting candidates for further investigation.

Elamipretide (SS-31)

Elamipretide is a mitochondria-targeting peptide that interacts with cardiolipin, an important component of the mitochondrial inner membrane.

Its proposed benefits include:

  • Supporting mitochondrial energy production

  • Reducing mitochondrial oxidative stress

  • Improving cellular energy efficiency

  • Potentially supporting cardiac muscle function

Small human studies in patients with heart failure have produced encouraging physiological findings, although they have not established prevention of heart attacks or regression of coronary plaque.

For patients interested in mitochondrial health, elamipretide represents an important area of cardiovascular research.

Thymosin Beta-4

Thymosin beta-4 is a naturally occurring peptide involved in tissue repair and cellular migration.

Experimental cardiovascular research suggests potential effects involving:

  • Cardiomyocyte survival

  • Blood vessel formation and endothelial repair

  • Regulation of inflammatory pathways

  • Reduction of fibrosis

  • Tissue recovery following ischemic injury

These mechanisms make thymosin beta-4 an interesting research candidate for cardiovascular repair.

Where Peptides Fit Into Our Approach

We believe these mechanisms justify continued investigation and individualized discussions about emerging cardiovascular therapies.

However, neither peptide has established clinical benefit for treating coronary calcium or preventing cardiovascular events. Their use for these purposes remains investigational, with important regulatory, product-quality, and safety considerations.

They should not replace proven preventive treatments. Patients interested in these therapies can discuss the available evidence, uncertainties, and appropriate clinical research opportunities with our team.

7. Do You Need More Cardiac Testing?

Not necessarily.

A high calcium score does not automatically mean you need a stress test, cardiac catheterization, or coronary stent.

For an asymptomatic patient with nonobstructive coronary disease, the most appropriate strategy is often intensive preventive treatment and ongoing clinical monitoring.

Additional testing becomes more important when symptoms suggest impaired blood flow.

Symptoms that warrant evaluation include:

  • Chest discomfort, particularly with exertion

  • Unexplained shortness of breath

  • A meaningful decline in exercise tolerance

  • New exertional pressure or discomfort in the arm, jaw, or back

New or severe symptoms require prompt assessment; possible heart attack symptoms require emergency care.

We also generally avoid repeating coronary calcium scans simply to judge whether treatment is working. Changes in calcification do not reliably reflect changes in plaque stability or cardiovascular risk.

Instead, we follow measurable treatment targets and your overall clinical progress.

8. Our Long-Term Treatment Strategy

At Revolution Health, we approach elevated coronary calcium as evidence that cardiovascular prevention deserves serious attention.

Our strategy is to:

  1. Reduce atherogenic cholesterol exposure through appropriate medication and metabolic treatment.

  2. Identify and optimize cardiovascular risk factors, including inflammation, insulin resistance, blood pressure, and visceral fat.

  3. Improve cardiovascular fitness and metabolic health through individualized nutrition, exercise, and lifestyle recommendations.

  4. Consider complementary therapies, including IV vitamin C and emerging mitochondrial or repair-focused interventions, when appropriate.

  5. Monitor progress through laboratory testing, body composition, blood pressure, symptoms, and clinical reassessment.

We do not expect every patient to need every treatment.

Our objective is to build a personalized plan that addresses the factors most likely to influence your cardiovascular health.

The Bottom Line: Your Calcium Score Is Not Your Destiny

An elevated coronary calcium score tells us that atherosclerosis is already present.

It does not tell us that a heart attack is inevitable.

With appropriate treatment, we can meaningfully reduce cardiovascular risk, improve metabolic health, and work toward stabilizing existing coronary disease.

The most important step is taking the results seriously and developing a comprehensive prevention strategy rather than waiting for symptoms to appear.

Ready to Take Control of Your Cardiovascular Health?

At Revolution Health & Wellness Clinic, we combine advanced cardiovascular risk assessment, individualized medical treatment, metabolic optimization, and integrative strategies to help patients protect their long-term health.

If you have an elevated coronary calcium score, we can help you understand your results and develop a personalized treatment plan.

Get Started With Revolution Health


Scientific References

  1. American College of Cardiology/American Heart Association. 2026 Guideline on the Management of Dyslipidemia. Verify final bibliographic details before publication.

  2. Budoff MJ, et al. Long-term prognosis associated with coronary calcification: observations from the Multi-Ethnic Study of Atherosclerosis (MESA). European Heart Journal. 2018;39:2401–2408.

  3. Blaha MJ, et al. The importance of coronary artery calcium scoring for cardiovascular risk assessment. Journal of the American College of Cardiology. 2022.

  4. Nasir K, et al. Implications of coronary artery calcium testing among statin candidates. Journal of the American College of Cardiology. 2015;66:1657–1668.

  5. Cainzos-Achirica M, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention. Circulation. 2020;141:1541–1553.

  6. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: preventive medication. JAMA. 2022;327:1577–1584.

  7. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. European Heart Journal. 2017;38:2459–2472.

  8. Nicholls SJ, et al. Effect of statin therapy on coronary plaque composition and atherosclerosis progression. Journal of the American College of Cardiology. 2018.

  9. Duque M. Cardiac Peptides. Educational lecture materials, 2026. Includes discussion of vitamin C, elamipretide, and thymosin beta-4.

  10. Daubert MA, et al. A randomized placebo-controlled trial of elamipretide in patients with heart failure with reduced ejection fraction. Circulation: Heart Failure. 2017;10.

  11. Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004;432:466–472.

Medical disclaimer: This article provides general educational information and does not replace individualized medical evaluation. Treatment decisions depend on your medical history, risk factors, medications, and clinical findings.